Floatz logo

Sirolimus

Skin Squamous Cell Carcinoma

Dana-Farber Cancer InstituteSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Skin Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Prednisone
Dana-Farber Cancer Institute
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 3BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3BB
Indocyanine Green
Institut de Cancérologie de Lorraine
Phase 3BB
Everolimus
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Sirolimus is also rated in:

tuberous sclerosisActive
BBB
Indicative · Phase 3
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BB
Indicative · Phase 2
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →